Japanese study highlights HER2 and BRAF targets in canine lung cancer

A newly published study from Japan adds fresh evidence that HER2 and BRAF are the most actionable-looking hotspot mutations in canine pulmonary adenocarcinoma. Writing in Veterinary Sciences, the authors analyzed 20 surgically resected tumors and three canine pulmonary adenocarcinoma cell lines, finding HER2 V659E in 15% of cases, BRAF V595E in 15%, and KRAS G12V in 5%, with no hotspot PIK3CA mutations detected. In lab testing, the BRAF V595E-mutant AZACL2 cell line was more sensitive to dabrafenib and MEK inhibitors including trametinib than BRAF wild-type lines, supporting the idea that some of these tumors are driven by MAPK-pathway signaling. (mdpi.com)

That matters because primary pulmonary adenocarcinoma in dogs is uncommon, and systemic treatment options remain limited. Over the past several years, canine lung carcinoma has drawn more attention in comparative oncology as investigators have described recurrent molecular alterations that resemble subsets of human lung cancer. Earlier work identified recurrent activating HER2 mutations, especially V659E, in canine pulmonary adenocarcinoma and linked those alterations to downstream signaling and in vitro response to HER2 inhibition. A recent review also described canine lung carcinoma as an area where molecular profiling may help refine diagnosis and future treatment strategies. (pmc.ncbi.nlm.nih.gov)

The new Japanese dataset is relatively small, but it helps answer an important question: whether mutation patterns seen in prior cohorts hold up across geography. According to the paper, they largely do. The authors conclude that the mutation spectrum was broadly consistent with previous reports, which supports a conserved molecular landscape rather than a distinctly regional one. That consistency is useful for clinicians and researchers thinking about whether targeted testing approaches developed in one population might be relevant in another. (mdpi.com)

The study's most clinically interesting detail may be the drug-sensitivity work around BRAF V595E. While HER2 has gotten much of the attention in canine pulmonary adenocarcinoma, this paper points to a second potentially targetable subgroup. The BRAF-mutant cell line's increased sensitivity to dabrafenib and trametinib doesn't prove clinical benefit in dogs, but it does provide biologic support for considering BRAF and downstream MAPK signaling in future translational studies. More broadly, a recent systematic review of tyrosine kinase inhibitors in canine solid tumors noted growing interest in molecularly selected use of targeted agents, while also underscoring how thin the clinical evidence base still is. (mdpi.com)

There wasn't much published outside commentary on this specific paper at the time of writing, but related expert literature gives some context. A 2026 Veterinary and Comparative Oncology report found HER2 mutations in canine pulmonary adenocarcinoma were associated with favorable prognosis after surgical resection, suggesting mutation status may eventually have value beyond treatment selection alone. Separately, prior HER2-focused research showed that HER2 V659E is not just recurrent, but functionally activating, which is an important distinction when clinicians are deciding whether a mutation is likely to be biologically meaningful. (onlinelibrary.wiley.com)

Why it matters: For veterinary professionals, this study supports a more precision-oncology mindset in a disease where treatment decisions are often constrained by limited evidence and few systemic options. If a dog with pulmonary adenocarcinoma progresses after surgery, presents with metastatic disease, or isn't a surgical candidate, molecular profiling for HER2 and BRAF may become increasingly relevant, particularly at referral centers and in academic settings. The study doesn't establish a standard of care, and it doesn't show patient outcomes with targeted drugs, but it does strengthen the rationale for testing and for clinical-trial enrollment when available. It may also help frame conversations with pet parents who are asking whether advanced diagnostics could meaningfully expand options. (mdpi.com)

There are still clear limitations. This was a 20-case surgical cohort, not a prospective treatment trial, and the therapeutic signal came from cell-line experiments rather than clinical responses in dogs. The absence of PIK3CA hotspot mutations in this series is notable, but it shouldn't be overgeneralized given the sample size and the study's hotspot-focused design. As with much of veterinary precision oncology, the practical questions now are less about whether these mutations exist and more about when to test, which assays to use, how to access targeted drugs, and which patients are most likely to benefit. (mdpi.com)

What to watch: The field now needs prospective, mutation-stratified studies in dogs with recurrent, unresectable, or metastatic lung adenocarcinoma, along with more work on assay standardization and real-world access to targeted therapies in referral practice. If those data emerge, HER2 and BRAF could move from interesting biomarkers to clinically useful decision tools. (mdpi.com)